Xarelto (rivaroxaban) - Increase In All-cause Mortality, Thromboembolic And Bleeding Events In Patients After Transcatheter Aortic Valve Replacemen

XARELTO Recall Summary Health Canada is recalling XARELTO (rivaroxaban) because studies show that patients who take this blood thinner after receiving a transcatheter aortic valve replacement procedure have higher rates of death, blood clots, and bleeding compared to other treatment options. This recall affects XARELTO distributed across Canada. Patients who have had this procedure and are currently taking XARELTO should consult their healthcare provider.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2018-12-20

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/996a37e3-99ed-45de-bee0-b54f62a2962d